Total Valuation
Alterity Therapeutics has a market cap or net worth of €68.92M. The enterprise value is €32.34.
Market Cap€68.92M
Enterprise Value€32.34
Share Statistics
Alterity Therapeutics has 218,500,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding218,500,430
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Alterity Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -34.25%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-34.25%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee604.32K
Profits Per Employee-1.35M
Employee Count9
Asset Turnover0.12
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Alterity Therapeutics is ―. Alterity Therapeutics’s PEG ratio is 0.08.
PE Ratio―
PS Ratio11.76
PB Ratio1.51
Price to Fair Value1.51
Price to FCF-5.59
Price to Operating Cash Flow-8.16
PEG Ratio0.08
Income Statement
In the last 12 months, Alterity Therapeutics had revenue of 5.44M and earned -12.15M in profits. Earnings per share was -0.10.
Revenue5.44M
Gross Profit5.31M
Operating Income-14.57M
Pretax Income-12.08M
Net Income-12.15M
EBITDA-14.63M
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was -12.98M and capital expenditures 10.62M, giving a free cash flow of -2.36M billion.
Operating Cash Flow-12.98M
Free Cash Flow-2.36M
Free Cash Flow per Share-0.01
Dividends & Yields
Alterity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.91
52-Week Price Change60.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)142.00K
Important Dates
Alterity Therapeutics upcoming earnings date is Mar 4, 2027, TBA (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMar 4, 2027
Ex-Dividend Date―
Financial Position
Alterity Therapeutics as a current ratio of 12.98, with Debt / Equity ratio of 0.30%
Current Ratio12.98
Quick Ratio12.98
Debt to Market Cap0.00
Net Debt to EBITDA2.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Alterity Therapeutics has paid 68.06K in taxes.
Income Tax68.06K
Effective Tax Rate>-0.01
Enterprise Valuation
Alterity Therapeutics EV to EBITDA ratio is -2.12, with an EV/FCF ratio of -2.70.
EV to Sales5.69
EV to EBITDA-2.12
EV to Free Cash Flow-2.70
EV to Operating Cash Flow-2.70
Balance Sheet
Alterity Therapeutics has €49.20M in cash and marketable securities with €163.91K in debt, giving a net cash position of €49.04M billion.
Cash & Marketable Securities€49.20M
Total Debt€163.91K
Net Cash€49.04M
Net Cash Per Share€0.22
Tangible Book Value Per Share€0.33
Margins
Gross margin is 96.82%, with operating margin of -267.96%, and net profit margin of -223.35%.
Gross Margin96.82%
Operating Margin-267.96%
Pretax Margin-222.10%
Net Profit Margin-223.35%
EBITDA Margin-269.05%
EBIT Margin-269.57%
Analyst Forecast
The average price target for Alterity Therapeutics is €0.59, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€0.59
Price Target Upside95.64% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-12.94%